Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

All aboard: Will molecular tumor boards help cancer patients?

Nature Medicine volume 21, pages 655–656 (2015)Cite this article

Subjects

A look at the transcriptome of his tumor found a gene—FLT3--that was overexpressed, likely due to acquired mutations in regulatory elements of the gene. The discovery allowed his colleagues to match his leukemia's FLT3 mutation with a drug used in kidney cancer, putting Wartman into remission and allowing a second stem cell transplant, this time from an unrelated donor, which got him on the road back to health.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Jeanne Erdmann is an independent journalist in Wentzville, Missouri, who writes about science and health.,

    Jeanne Erdmann

Authors
  1. Jeanne Erdmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Erdmann, J. All aboard: Will molecular tumor boards help cancer patients?. Nat Med 21, 655–656 (2015). https://doi.org/10.1038/nm0715-655

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0715-655

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer